Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
Study of Select Combinations in Adults With Myelofibrosis
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04283526
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 25
- Registration Number
- NCT04282187
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04279379
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, China
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT04277442
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Syntrix Biosystems, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT04245397
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸AdventHealth Medical Group & Bone Marrow Transplant at Orlando, Orlando, Florida, United States
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04233294
- Locations
- 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 128
- Registration Number
- NCT04229979
- Locations
- 🇺🇸
Mayo Clinic Jacksonville Florida, Jacksonville, Florida, United States
🇫🇷CHU de Caen, Caen, France
🇬🇷General Hospital of Athens "Evaggelismos", Athens, Greece
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Benjamin Tomlinson
- Target Recruit Count
- 20
- Registration Number
- NCT04187703
- Locations
- 🇺🇸
Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
- Conditions
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Acute Myeloid LeukemiaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04188405
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
- Conditions
- Interventions
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 5
- Registration Number
- NCT04146038
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.